9-Me-BC

9-Me-BC (9-methyl-beta-carboline, chemically 9-methyl-9H-pyrido[3,4-b]indole) is a methylated member of the beta-carboline family, a group of pyridoindole alkaloids built on a tryptophan-derived tricyclic ring system. Beta-carbolines occur both endogenously in human brain, plasma, and cerebrospinal fluid and exogenously in foods such as cooked meat, coffee, and tobacco smoke ^[1]. Most members of the family were historically studied as potential neurotoxins, and elevated levels have been associated with Parkinson's disease. Against that backdrop, 9-Me-BC stands out as the exception; it was the first beta-carboline identified as exerting neuroprotective and neuron-differentiating rather than toxic effects ^[1].

The compound's structure, a beta-carboline core carrying a methyl group at the 9-nitrogen position, is central to its unusual profile, and its photophysical and chemical behavior have been characterized alongside related N-methyl-beta-carbolines ^[6]. Research on 9-Me-BC has centered on the dopaminergic system. In cell culture it increases the number of mature dopaminergic neurons and switches on a broad program of neurotrophic and transcription factors that guide dopaminergic differentiation ^[1]. In living animals it has shown restorative effects, reversing dopamine loss in a toxin model of Parkinson's disease and improving mitochondrial respiratory-chain function ^[3]. Separate work found that it acts as a cognitive enhancer, improving spatial learning while raising hippocampal dopamine and promoting the growth of dendrites and synapses ^[4].

Because of this rare multimodal profile, 9-Me-BC has been proposed as a candidate anti-Parkinson drug and is widely discussed as a dopaminergic nootropic ^[2]. Its regulatory status is that of an experimental research compound; it is not an approved medicine or dietary supplement and is sold chiefly as a research chemical in powder or capsule form. Investigations remain preclinical, spanning cell cultures, astrocytes, and rodent models, with no completed human clinical trials reported in the reviewed literature ^[2][5].

HUMAN SAFETY DATA: none. No published human pharmacokinetics, no bioavailability, no half-life, no brain-penetration data, no organ toxicity data, no drug-interaction studies and no adverse-event series. Every risk below is inferred from in vitro or animal work and is labelled as such.

1. MAO-A inhibition and its interaction class. 9-Me-BC inhibits human MAO-A with an IC50 of 1 µM (PMID 32285253). Whether the doses people take produce meaningful MAO-A inhibition in a living human has never been measured. If it does, the standard MAO-A hazards apply: hypertensive reaction with tyramine-rich foods, and serotonin toxicity when combined with SSRIs, SNRIs, MAOIs, triptans, tramadol, dextromethorphan, linezolid or St John's wort. This is a mechanistic inference, not an observed event.

2. Metabolic conversion into a known neurotoxin. This is the most serious and least discussed risk. Brain β-carboline-2-N-methyltransferase, identified as phenylethanolamine N-methyltransferase, uses 9-Me-BC as a substrate (KM 75 µM) and 2N-methylates it into 2,9-dimethyl-β-carbolinium, a quaternary MPP+-like cation that inhibits mitochondrial complex I and kills dopaminergic neurons (PMID 9016836, PMID 11900856). The same research group that reports 9-Me-BC's benefits uses 2,9-dimethyl-β-carbolinium as the toxin they are protecting against. How much of an oral dose is converted in humans has never been measured.

3. Photosensitisation and DNA damage. Under UVA light, 9-methyl-norharmane damages DNA, producing oxidised purine bases in large excess over pyrimidines, single-strand breaks, abasic sites, and cyclobutane pyrimidine dimers by triplet energy transfer (PMID 23842892). Beta-carbolines are efficient photosensitisers. This is the basis for the widespread sun-avoidance advice, though whether it is relevant at oral supplement doses in skin has not been quantified.

4. Narrow window in vitro. 90 µM was optimal but 150 µM cut TH-positive neuron numbers by 50% in astrocyte-depleted cultures (PMID 32285253); the authors attribute this to loss of astrocytic shielding at overdose.

REGULATORY STATUS: - Not approved as a medicine in any jurisdiction. European and Australian official medicines control laboratories classify it as a research chemical with no approved status in the EU or Australia, and found it circulating largely on the illegal market presented as a dietary supplement (PMID 40558871). - Not a scheduled or controlled substance in the US or UK in any source located. - WADA: NOT named on the Prohibited List. A 2025 review co-authored by the Polish Anti-Doping Agency places 9-Me-BC in its table of substances with "unclear" status, and notably does not list it as presumed to meet WADA criteria by analogy to any prohibited substance (PMID 41048238). Because the Prohibited List is open-ended and section S0 covers non-approved substances with no current regulatory approval for human therapeutic use, an unapproved research chemical can fall under S0. Athletes should treat 9-Me-BC as unresolved and risky, not as cleared.

Beta-carbolines were first studied as suspected endogenous and dietary neurotoxins thought to contribute to Parkinson's disease, which made the discovery that one member of the family did the opposite especially notable. Working at the Technical University of Dresden in Germany, Gabriele Gille, Heinz Reichmann and colleagues characterized 9-methyl-beta-carboline through the late 2000s and found that this simple methylated derivative stimulated, protected and even helped regenerate dopaminergic neurons in cell and animal models rather than harming them. The wider evidence for its stimulatory, neurotrophic, monoamine-oxidase-inhibiting and anti-inflammatory actions was consolidated in a 2011 review by Polanski, Reichmann and Gille that framed it as a possible new anti-Parkinson agent. It has never advanced to human clinical trials and remains an experimental research compound.

9-Me-BC enjoys a distinctive reputation as the rare beta-carboline that flips the family's usual toxicity into benefit, and it is often described as one of the most intriguing dopaminergic nootropics under study. Enthusiasts and researchers alike point to its unusual multimodal profile; in a single molecule it appears to raise dopamine, induce neurotrophic factors such as BDNF, improve mitochondrial complex I activity and dampen neuroinflammation, a combination that sets it apart from single-target dopaminergics. That said, essentially all of the supporting data come from cell cultures and rodents, so its effects and safety in people are genuinely unproven. It remains best regarded as a promising but early-stage compound whose appeal rests on a compelling preclinical story.